MIRA
MIRA Pharmaceuticals, Inc.NASDAQHealthcare$1.03+0.00%OpenMarket Cap: $43.3M
As of 2026-04-09
Valuation
P/E (TTM)
—
PEG
—
P/B
2.37
P/S
0.00
EV/EBITDA
-3.62
DCF Value
$0.27
FCF Yield
-10.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-646.3%
ROA
-288.4%
ROIC
-101.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $4.7M | $-6.0M | $0.03 | — |
| FY 2025 | $0.00 | NaN% | $-10.5M | $-10.4M | $-1.35 | — |
| Q3 2025 | $0.00 | NaN% | $-1.3M | $-22.7M | $-1.18 | — |
| Q2 2025 | $0.00 | NaN% | $-1.5M | $-1.5M | $-0.09 | — |
| Q1 2025 | $0.00 | NaN% | $-1.8M | $-1.8M | $-0.11 | — |
| Q4 2024 | $0.00 | NaN% | $-2.4M | $-2.4M | $-0.16 | — |
| FY 2024 | $0.00 | NaN% | $-8.0M | $-7.9M | $-0.51 | — |
| Q3 2024 | $0.00 | NaN% | $-2.1M | $-2.0M | $-0.14 | — |
| Q2 2024 | $0.00 | NaN% | $-1.7M | $-1.7M | $-0.11 | — |
| Q1 2024 | $0.00 | NaN% | $-1.8M | $-1.7M | $-0.09 | — |
| Q4 2023 | $0.00 | NaN% | $-3.1M | $-5.8M | $-0.39 | — |
| FY 2023 | $0.00 | NaN% | $-8.5M | $-12.0M | $-0.65 | — |